Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 12/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27487118 | 0.85 | HCAR3 (0.63) | TSHRCASP6HCAR3PDK1LMNA | |
| SCHEMBL8215974 | 0.83 | HCAR3 (0.64) | TSHRCASP6HCAR3PLA2G4BPDK1 | |
| SCHEMBL21824057 | 0.83 | ALDH1A1 (0.58) | TSHRCASP6HCAR3PDK1LMNA | |
| SCHEMBL9779790 | 0.82 | HCAR3 (0.62) | TSHRCASP6HCAR3PLA2G4BPDK1 | |
| SCHEMBL7575190 | 0.82 | HCAR3 (0.62) | TSHRCASP6HCAR3PLA2G4BPDK1 | |
| SCHEMBL6180268 | 0.82 | HCAR3 (0.64) | TSHRCASP6HCAR3PDK1LMNA | |
| SCHEMBL20757 | 0.81 | PDK1 (0.68) | TSHRCASP6HCAR3PDK1LMNA | |
| SCHEMBL2974692 | 0.80 | HCAR3 (0.53) | TSHRCASP6HCAR3LMNA | |
| SCHEMBL177446 | 0.80 | HCAR3 (0.53) | TSHRCASP6HCAR3PLA2G4BPDK1 | |
| SCHEMBL16129649 | 0.80 | HCAR3 (0.56) | TSHRCASP6HCAR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855713-B2 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003024451-A1 | 2-(2-PHENYLETHYL)-BENZIMIDAZOLE-5-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | TPSAB1, PRSS3, TPSD1 | TSHR 969/4885CASP6 360/4885HCAR3 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.